EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Fluoroquinolone Prophylaxis in Children With Cancer: A Pro/Con Discussion

Eleana Vasileiadi, Kevin M Lloyd iD, Brian T Fisher iD, Benjamin Hanisch iD

Journal of the Pediatric Infectious Diseases Society · 2024

DOI: 10.1093/jpids/piae077 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2024. Verfasst von Eleana Vasileiadi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Disease, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Antibiotic Prophylaxis, Anti-Bacterial Agents, Levofloxacin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There are conflicting recommendations on whether to use or not to use fluoroquinolone prophylaxis in pediatric oncology patients. An international pediatric clinical practice guideline (CPG) recommends administering levofloxacin prophylaxis in patients with acute myeloblastic leukemia and relapsed acute lymphoblastic leukemia receiving intensive chemotherapy as this practice has been found to reduce episodes of fever and bacteremia. A separate European CPG does not recommend levofloxacin prophylaxis because of concerns for adverse effects, including potentiation of fluoroquinolone resistance and possible increased resistance to other classes of antibiotics. The nuance of the decision to give or not give prophylaxis is discussed in the context of published evidence defining the risks and benefits of levofloxacin prophylaxis for pediatric leukemia patients at high risk for bacterial infection. Knowledge gaps are also identified to guide further investigations to optimize the use of fluoroquinolone prophylaxis in pediatric patients receiving chemotherapy for cancer or undergoing a hematopoietic cell transplantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibiotic ProphylaxisAnti-Bacterial AgentsLevofloxacinHumansChildFluoroquinolonesPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcutePractice Guidelines as TopicNeoplasmsBacteremiaHematopoietic Stem Cell TransplantationBacterial Infections

Stichwörter der Autor:innen

antibiotic resistancefluoroquinolonesimmunocompromised hostpediatric leukemiaprophylaxis

Substanzen

Anti-Bacterial AgentsLevofloxacinFluoroquinolones

Autor:innen und Institutionen

  • Division of Infectious Disease, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Department of Pediatric Infectious Diseases, Children's National, Washington, District of Columbia, USA.
  • Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

ORCID-Profile: Kevin M Lloyd, Brian T Fisher, Benjamin Hanisch

Zitieren

APA

Vasileiadi, E., Lloyd, K. M., Fisher, B. T., & Hanisch, B. (2024). Fluoroquinolone Prophylaxis in Children With Cancer: A Pro/Con Discussion. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piae077

Vancouver

Vasileiadi E, Lloyd KM, Fisher BT, Hanisch B. Fluoroquinolone Prophylaxis in Children With Cancer: A Pro/Con Discussion. Journal of the Pediatric Infectious Diseases Society. 2024. doi:10.1093/jpids/piae077

BibTeX
@article{Vasileiadi2024,
  author = {Vasileiadi, Eleana and Lloyd, Kevin M and Fisher, Brian T and Hanisch, Benjamin},
  title = {Fluoroquinolone Prophylaxis in Children With Cancer: A Pro/Con Discussion},
  journal = {Journal of the Pediatric Infectious Diseases Society},
  year = {2024},
  doi = {10.1093/jpids/piae077}
}
Kostenlos starten →